All In Biotech

Drug Trial Radar · NCT06621251

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection

Phase 2 Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Chronic Prosthetic Joint Infection of the Knee or Hip Without Exchange Arthroplasty

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 8, 2025

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Trellis Bioscience LLCIndustry
Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.

Conditions

  • Prosthetic Joint Infections of Hip
  • Prosthetic Joint Infections of Knee

Interventions

  • TRL1068 (calpurbatug), a human monoclonal antibodyDrug

    A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

  • DAIRProcedure

    DAIR procedure will be performed between days 15-22

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of TRL1068 in eliminating the need for an SoC 2-stage exchange arthroplastyTime frame: Day 365

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • OrthoArizona

    Gilbert, Arizona

  • UCLA

    Los Angeles, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Gulfcoast Research Institute

    Sarasota, Florida

  • Phoenix Clinical Research

    Tamarac, Florida

  • Sinai Hospital Baltimore

    Baltimore, Maryland

  • New England Baptist Hospital

    Boston, Massachusetts

  • University of Rochester

    Rochester, New York

  • M3 Wake Research Associates

    Wilmington, North Carolina

  • North Texas Medical Research Institute

    Rockwall, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.